Azoximer bromide

Azoximer bromide, sold by the trade name Polyoxidonium, is a water-soluble cationic polymer, adjuvant[1] used in Russia and Georgia in treatment and prophylaxis of immune disorder. It is a N-oxidized polyethylene–piperazine derivative. The effectiveness of polyoxidonium has not been confirmed by independent clinical studies that meet modern standards of evidence-based medicine: there are no double-blind randomized and placebo-controlled studies with a sufficient number of participants and the publication of results in scientific journals with a high impact factor.[2]

Azoximer bromide
Clinical data
Other namesPolyoxidonium, Synpol
ATC code
Pharmacokinetic data
Bioavailabilityup to 89%
Elimination half-life25.4 hours (intravenous routes)
Identifiers
IUPAC name
  • Poly[[1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide]ethylene- co-[(piperazin-1,4-diyl 1-oxide)ethylene]]
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula[[C8H15BrN2O2]x[C6H12N2O]y]n
Molar mass60000–100000 g/mol

Azoximer bromide is registered in US Patent-5503830 from 1996,[3][4][5] in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00.[6]

History

Polyoxidonium was created at the State Scientific Center of the Institute of Immunology of the Ministry of Health of the Russian Federation.[7] It is produced by NPO Petrovax Pharm LLC.[8]

References
  1. Powell BS, Andrianov AK, Fusco PC (January 2015). "Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes". Clinical and Experimental Vaccine Research. 4 (1): 23–45. doi:10.7774/cevr.2015.4.1.23. PMC 4313107. PMID 25648619.
  2. Shainyan K (2004-11-08). "Оздоровление с риском для жизни" [Wellness at the risk of life]. Kommersant (in Russian). Retrieved 2021-04-03.
  3. https://www.google.com/patents/about?id=s9cfAAAAEBAJ&dq=US+5503830
  4. http://www.wikipatents.com/US-Patent-5503830/compounds-having-immunostimulating-activity-and-methods-of-use-thereof%5B%5D
  5. http://www.freepatentsonline.com/EP0789586.html
  6. State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort, CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM, Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort Moscow – 2003
  7. Некрасов А. В., Пучкова Н. Г., Иванова А. С. и др. Производное поли-1,4-этиленпиперазина, обладающее иммуномодулирующей, противовирусной и антибактериальной активностью. Пат. РФ № 2073031, 1997.
  8. http://petrovax.com/medication/catalog/polyoxydonium/
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.